推进循环肿瘤细胞和肺癌的发展

• 作 者: T. Jeroen N.Hiltermann Anthonie J.van der Wekken Harry J. M.Groen 王慧娟 董艳鹏
• 机 构: Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen,Groni
• 出 处: 国际病理科学与临床杂志
• 发表日期: 2013年05期
• 关键词: 循环肿瘤细胞 growth factor receptor kinase inhibitors 靶向治疗 内皮生长因子受体 酪氨酸激酶抑制剂 非小细胞肺癌 lu

肺癌仍然是世界上最致命的肿瘤。每年有超过100万人因此病丧生[1]。(肺)癌最常见的死因是转移癌。肿瘤细胞在起病部位之外的组织中传播和生长,肿瘤负荷迅速增加[2]。非小细胞肺癌(non-small cell lung carcinoma,NSCLC)约占所有肺癌病例的85%,并且是全球癌症相关死亡的首要原因。约70%的患者在就诊时已达疾病晚期,

Lung cancer remains the most deadly tumor in the world. More than 1 million people die each year [1]. The most common cause of death from lung cancer is metastatic cancer. Tumor cells spread and grow in tissues other than the site of onset, resulting in a rapid increase in tumor burden [2]. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is the leading cause of cancer-related deaths worldwide. About 70% of patients at the time of treatment have reached advanced stage of disease,